Abstract Anti-tumor Necrosis Factor (anti-TNF) agents are the backbone treatment of
moderate to severe cases of inflammatory bowel disease. One of the main drawbacks of …

The increasing incidence of inflammatory bowel disease (IBD) globally has redirected the
healthcare system's focus towards safe and affordable pharmacological interventions. The …

Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven
to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) …

Introduction: Biologic antagonists to tumor necrosis factor alpha (TNF-α) are effective
medications and have become well established in the treatment of both Crohn's disease and …

Abstract On February 9, 2016, the Food and Drug Administration Arthritis Advisory
Committee recommended by a vote of 21 to 3, that the biosimilar to infliximab, CT-P13, be …

Within the last 20 years, tumour necrosis factor inhibitors have been proven to be effective in
achieving and maintaining clinical and endoscopic remission in patients with Crohn's …

The management of chronic inflammatory disorders including inflammatory bowel diseases
has been revolutionized by the entrance of biological agents now almost 20 years ago. Over …

The introduction of biologic therapies has revolutionized the treatment of inflammatory bowel
disease (IBD) and has significantly improved the disease course and outcomes for many …

The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the
management of inflammatory bowel disease in those cases which are refractory to …

The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was
introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five …